Date(s) - 17/09/2014 - 20/09/2014
09:30 - 17:00
UCL Institute of Neurology
This will be the fourth major international meeting to focus on cerebral amyloid angiopathy (CAA); the first was held in Reyjavik, Iceland in August 2007, the second in Los Angeles, California in May 2010, and the third in Leiden, Netherlands in October 2012.
Queen Square is recognized worldwide as a unique centre of excellence in clinical neurology and neurosciences research. Its long and rich heritage dates back to the foundation of the National Hospital in 1859. Researchers from Queen Square have made major contributions to themes underpinning our understanding of cerebral amyloid angiopathy, including the amyloid hypothesis of Alzheimers disease, hereditary forms of Alzheimer’s disease, and the specific genetic form of cerebral amyloid angiopathy, Familial British Dementia.
The conference goals will be to bring together the leading international experts in ß-amyloid metabolism, vascular biology, neuropathology, circulating biomarkers, stroke genetics, brain imaging, and the clinical manifestations of cerebrovascular disease to present and discuss cutting-edge data in this rapidly developing field. The conference will aim to authoritatively summarize the state-of-the art in these key aspects of CAA research and to move the field towards identification of disease-modifying therapies.
Anticipated key themes will include: biomarkers for early detection and monitoring disease activity or progression; mechanisms of vascular amyloid accumulation; progress in discovery and testing of candidate disease-modifying biological treatments for CAA; and how CAA interacts with and contributes to Alzheimer’s disease.
An overarching goal will be the development of international networks to investigate CAA in large-scale studies. The atmosphere for discussion is anticipated to be interactive, informal, and lively, with extensive opportunities for forming new collaborations and relationships within the growing CAA scientific and clinical communities.